A de-risked, best-in-class oral TYK2 inhibitor with biologic-like psoriasis efficacy—and the next battle is payer access, labeling, and scale.
Overview
Alumis (ALMS) is transitioning from a speculative clinical-stage biotech to a de-risked, pre-commercial immunology company after positive pivotal Phase 3 ONWARD psoriasis data for envudeucitinib (formerly ESK-001). The company’s value proposition centers on a proprietary precision immunology platform and a next-generation **allosteric TYK2 inhibitor** designed to avoid the safety liabilities that burden first-generation JAK inhibitors (malignancy, thrombosis, MACE warnings). By binding TYK2’s JH2 regulatory domain, envudeucitinib targets IL-23/IL-12/Type I interferon signaling with high selectivity. In moderate-to-severe plaque psoriasis—a major commercial beachhead—Week 24 results of ~74% PASI 75 and ~65% PASI 90 suggest best-in-class oral efficacy and potential to narrow the efficacy gap vs injectables. The pipeline adds substantial upside optionality via lupus (Phase 2b LUMUS, readout Q3 2026) and neuro-immunology through a CNS-penetrant TYK2 program (A-005). Financially, Alumis strengthened its balance sheet via the 2025 Acelyrin merger and a January 2026 upsized equity raise (~$345M gross), resulting in pro-forma cash of ~ $633M and runway into 2027—enough to fund the psoriasis NDA (H2 2026), lupus catalyst, and launch prep.